Isabelle Joyce de Lima Silva-Fernandes

Isabelle Joyce de Lima Silva-Fernandes

Auto-generated profile, based on publicly available information

Isabelle Joyce de Lima Silva-Fernandes

Papi Junior Street, Fortaleza, Brazil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2020 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
FOFrancisca Fernanda Barbosa Oliveira
Francisca Fernanda Barbosa Oliveira
PSPaulo Goberlânio de Barros Silva
Paulo Goberlânio de Barros Silva
RSRosane Oliveira de Sant’aNa
Rosane Oliveira de Sant’aNa
CAClarissa Gondim Picanço de Albuquerque
Clarissa Gondim Picanço de Albuquerque
MBMaria Júlia Barbosa Bezerra
Maria Júlia Barbosa Bezerra
MLMarcos Venicio Alves Lima
Marcos Venicio Alves Lima

27 January 2021 in Head and Neck Pathology
Verified
Journal Article
Closed access
PDF file
OFOsias Vieira de Oliveira Filho
Osias Vieira de Oliveira Filho
TDThinali Sousa Dantas
Thinali Sousa Dantas
ISIsabelle Joyce de Lima Silva-Fernandes
Isabelle Joyce de Lima Silva-Fernandes
MCMaria Do Perpétuo Socorro Saldanha Cunha
Maria Do Perpétuo Socorro Saldanha Cunha
AAAna Paula Negreiros Nunes Alves
Ana Paula Negreiros Nunes Alves
FSFabrício Bitu Sousa
Fabrício Bitu Sousa

13 July 2023 in APMIS
Verified
Journal Article
Closed access
PFPriscilla Mariana Freitas Aguiar Feitosa
Priscilla Mariana Freitas Aguiar Feitosa
CHCarlos Gustavo Hirth
Carlos Gustavo Hirth
ISIsabelle Joyce De Lima Silva‐Fernandes
Isabelle Joyce De Lima Silva‐Fernandes
CDConceição Aparecida Dornelas
Conceição Aparecida Dornelas

16 September 2025 in Brazilian Journal of Microbiology
Verified
Journal Article
Closed access
PDF file
ÁSÁlife Diêgo Lima Silva
Álife Diêgo Lima Silva
JMJulia Graziele Alves Marelli
Julia Graziele Alves Marelli
MLMaria Willaiara Lira Lopes
Maria Willaiara Lira Lopes
MRMyrella Tavares Rodrigues
Myrella Tavares Rodrigues
CLCecília Paz Lopes
Cecília Paz Lopes
MLMarcos Antonio Pereira de Lima
Marcos Antonio Pereira de Lima

1 June 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ISIsabelle Joyce de Lima Silva-Fernandes
Isabelle Joyce de Lima Silva-Fernandes
LALetícia Macedo Nicácio Andrade
Letícia Macedo Nicácio Andrade
ALArthur Ernani Saldanha e Oliveira Lima
Arthur Ernani Saldanha e Oliveira Lima
MBMaria Júlia Barbosa Bezerra
Maria Júlia Barbosa Bezerra
MLMaria Claudia dos Santos Luciano
Maria Claudia dos Santos Luciano
PSPaulo Goberlânio de Barros Silva
Paulo Goberlânio de Barros Silva
E20548 Background: Lung cancer has the highest incidence and mortality worldwide. In Brazil, it is the second most common, and individualized therapy, although more efficient than traditional chemotherapy, is still a challenge for health services, especially in developing countries, as socioeconomic disparities make access to genetic testing difficult or treatment. Thus, it is understood that greater knowledge about the genetic profile and therapeutic response of different populations can contribute to policy changes that guarantee expanded access to individualized therapy. Methods: the EGFR gene mutation status was correlated with clinical-epidemiological, socioeconomic, treatment, and survival parameters of patients with lung adenocarcinoma treated from 2014 to 2021 at an oncology referral center in northeastern Brazil. Data were obtained retrospectively from the patient's charts at the Hospital Haroldo Juaçaba/Instituto do Câncer do Ceará. The X²/Fisher and Log-Rank Mantel-Cox tests were used to associate clinical variables and overall survival curves. The Research Ethics Committee approved the research under protocol number 3.544.754. Results: 586 patients tested, 157 (26.8%) had an EGFR mutation, with exon 19 deletion (n = 83, 52.9%). the most frequent followed by L858R (n = 54, 34.4%) and others (n = 30, 12.8%). The EGFR mutation was inversely associated with smoking history (p < 0.001) and previous use of carboplatin plus paclitaxel (p < 0.001). The median overall survival was 33 (95%CI = 25-41) months, and the presence of a mutation was not associated with a worse outcome (p = 0.146). Interestingly, patients with sensitivity mutation who used gefitinib (64.1%) did not show a significant difference in overall survival (p = 0.218). However, when stratifying analyzes according to mutation type, it was observed that patients with exon 19 deletion treated with gefitinib had greater median overall survival (32, 95%CI = 27-37 months) than patients with this mutation not treated with gefitinib (median = 15, 95%CI = 2-25 months) (p < 0.001). Patients with the L858R type sensitivity mutation (p = 0.523) or other mutations (p = 0.439) did not experience significant benefits from gefitinib use. Conclusions: In the population studied, the exon 19 deletion was the most frequent and the only one associated with a substantial benefit from using gefitinib.

1 June 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
FOFrancisca Fernanda Barbosa Oliveira
Francisca Fernanda Barbosa Oliveira
PSPaulo Goberlânio de Barros Silva
Paulo Goberlânio de Barros Silva
FBFlávio da Silveira Bitencourt
Flávio da Silveira Bitencourt
RSRosane Oliveira Sant'Ana
Rosane Oliveira Sant'Ana
ISIsabelle Joyce de Lima Silva-Fernandes
Isabelle Joyce de Lima Silva-Fernandes
MLMarcos Venício Alves Lima
Marcos Venício Alves Lima
E22529 Background: Genetic tests have been increasingly requested to identify families at risk of hereditary cancer. In a family with a known mutation, the offspring of a carrier, whether male or female, have a 50% risk of inheriting the mutation. Most studies on the psychological implications associated with genetic testing have focused on women and few studies have focused on the male population. Methods: A total of 56 men with a personal history of cancer underwent screening for mutations in a panel of 31 genes associated with hereditary cancer. Assessment of quality of life (QoL) and levels of anxiety and depression was performed after patients received the genetic test result. For this, the HADS and WHOQOL-BREF scales were used. Wilcoxon, X², and Spearman correlation tests were used (SPSS v20.0 for Windows). Results: Of the 56 participants, 28.6% had a pathogenic mutation, 32.1% had a Variant of Undetermined Significance (VUS), and 39.3% had no mutation. The presence of the mutation was not associated with QoL (p = 0.967) or anxiety (p = 0.436) or depression (p = 0.945). Mean QoL was 77.95±7.38 (range = 50.00-95.20), mean anxiety was 5.14±2.62 (range = 1-14) and mean depression scores were 4.14±2.55 (range = 0-14). QoL was inversely correlated with levels of anxiety (p < 0.001, r = -0.496) and depression (p < 0.001, r = -0.494), parameters that were directly correlated (p = 0.037, r = 0.279). Most patients had QoL > 80 (n = 38, 67.9%), and only 16 (28.6%) and 13 (23.2%) men had HAD scores > 5. Conclusions: The result of carrying a mutation did not influence the quality of life and anxiety or depression levels in the male population evaluated. However, it was observed that levels of anxiety and depression can compromise the quality of life. The data from the present study reinforce the importance of considering the psychological aspects in the process of genetic investigation for hereditary cancer. In addition, it suggests that educational levels must be investigated to assess whether the low levels of anxiety and depression observed are associated with a low level of understanding of the clinical significance of carrying a pathogenic mutation.